Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)
Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)
To study the in vivo expression of dopamine D2 receptors in nonfunctioning pituitary adenoma
 and the predictive role of dopamine dopamine D2 receptors PET-MR imaging in the therapeutic
 effect of dopamine agonists（DA）.
Dopamine agonists are the first line therapy for prolactinoma,which are also effective in
 some cases of other subtypes of pituitary tumors. It had been showed that dopamine agonists
 inhibit prolactin secretion by binding to and activating dopamine D2 receptors. PET-MR
 combined MR images with PET function images is substantial to evaluate the expression of
 dopamine D2 receptors.The aim is to study the in vivo expression of dopamine D2 receptors in
 prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the
 therapeutic effect of dopamine agonists.
Inclusion Criteria:

 1. Normal serum pituitary hormone levels or mild increase of serum prolactin.

 2. Enhanced MRI shows a pituitary tumor and tumor diameter>1cm.

 3. Aged between 18 and 65 years old, either sex.

 4. Karnofsky performance status ≥ 70.

 5. The patient has signed the informed consent.

 Exclusion Criteria:

 1. Patients concomitantly taking the psychotropic drugs.

 2. Patients with parkinson disease and is taking dopaminergic agents.

 3. Patients with pituitary adenoma who received Gamma knife treatment.

 4. Pregnant or lactating women.

 5. Patients with poor compliance, who cannot implement the program strictly.

 6. History of allergic reactions attributed to compounds of similar chemical or biologic
 composition to cabergoline.

 7. Patients with claustrophobia. -